NSCLC — Adenocarcinoma

USMLE Step 1 trap: Incorrectly links adenocarcinoma exclusively to heavy smoking rather than recognizing its non-smoker association. Adenocarcinoma is the most common lung cancer in non-smokers and women, and is associated with EGFR and ALK mutations more than other subtypes.

Adenocarcinoma is the most common primary lung cancer overall, and the most common lung cancer in non-smokers and women. It arises from type II pneumocytes and Clara cells in the lung periphery — that peripheral location is a key identifier on USMLE Step 1 vignettes. Unlike squamous cell and small cell carcinomas, which tend to be central and strongly tied to heavy smoking, adenocarcinoma has a distinct epidemiologic and molecular profile that the exam exploits repeatedly.

The exam tests this topic from multiple angles: pure recall (location, cell of origin), histology interpretation (lepidic growth pattern and what it means on CT), molecular targets (EGFR vs. ALK vs. ROS1 and which drug matches which), and paraneoplastic syndromes like hypertrophic osteoarthropathy. Vignettes often describe a woman or a never-smoker with a peripheral nodule — that demographic framing is the signal to think adenocarcinoma first.

The trickiest area is the molecular biology. Students often conflate EGFR-targeted therapy with ALK-targeted therapy, or assume all lung cancers are driven by smoking and miss the EGFR/ALK angle in a non-smoker. The lepidic growth pattern is another common stumbling block — students default to thinking 'growth = invasion,' but lepidic growth is specifically non-invasive spread along intact alveolar walls. USMLE Step 1 rewards precision here, so the distinctions matter.

From real student decks

78%have cards covering this topic

57%have mature cards

Common misconceptions

Common mistake

Wrong: Adenocarcinoma is exclusively a disease of heavy smokers.

Right: Adenocarcinoma is the most common lung cancer in non-smokers and women, and is associated with EGFR and ALK mutations more than other subtypes.

Adenocarcinoma is actually the lung cancer you should think of first in a non-smoker — it is the most common lung cancer in people who have never smoked, and is more prevalent in women than other subtypes. Heavy smoking is more strongly linked to squamous cell carcinoma (central, keratinizing) and small cell carcinoma. The EGFR and ALK driver mutations that characterize many adenocarcinomas are enriched in non-smokers, which is why targeted therapy workup is especially important in that population.

Common mistake

Wrong: Lepidic growth pattern means the tumor invades and destroys alveolar walls.

Right: Lepidic growth means tumor cells spread along intact alveolar walls without stromal invasion, giving a 'ground-glass' appearance on CT.

Lepidic growth is explicitly non-destructive — the tumor cells use the alveolar wall as a scaffold and crawl along its surface, leaving the underlying structure intact. This is why it appears as ground-glass opacity on CT rather than a solid mass, and why in situ adenocarcinoma (formerly BAC) has a better prognosis. Invasive adenocarcinoma is a separate step that occurs when tumor cells break through the basement membrane into the stroma — lepidic pattern alone does not imply that has happened.

Common mistake

Gap: Fails to distinguish EGFR-targeted therapy from ALK-targeted therapy in adenocarcinoma

EGFR mutations are treated with erlotinib/gefitinib, while ALK rearrangements are treated with crizotinib; these are distinct targets requiring separate testing.

EGFR and ALK are completely distinct molecular targets requiring separate testing and separate drugs. EGFR mutations (most commonly exon 19 deletions or the L858R point mutation) are treated with first-generation TKIs erlotinib or gefitinib. ALK gene rearrangements — a chromosomal translocation creating a fusion protein — are treated with crizotinib (also active against ROS1 rearrangements). Testing for one does not tell you anything about the other, and the drugs are not interchangeable. On the exam, if a vignette specifies the mutation type, match it to the correct drug class.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know that adenocarcinoma is peripheral, arises from type II pneumocytes and Clara (club) cells, is the most common lung cancer in non-smokers, and disproportionately affects women and those with no significant smoking history.
Recognize adenocarcinoma histology on description: glandular formation, mucin production, and the lepidic growth pattern — where tumor cells spread along intact alveolar walls without destroying the underlying architecture, producing a ground-glass opacity on CT imaging.
Match the correct targeted therapy to each driver mutation: EGFR mutations (exon 19 deletion or L858R) respond to erlotinib or gefitinib (TKIs); ALK and ROS1 rearrangements respond to crizotinib; KRAS mutations currently lack effective targeted therapy. Know that adenocarcinoma is the subtype most commonly tested in the context of driver mutations.
Identify hypertrophic osteoarthropathy (periosteal new bone formation causing painful wrists/ankles, digital clubbing) as the paraneoplastic syndrome most classically associated with adenocarcinoma, and distinguish it from paraneoplastic syndromes tied to squamous cell or small cell carcinoma.

Can you avoid these mistakes?

A 47-year-old woman who never smoked presents with a 2 cm peripheral lung nodule found incidentally on CT. Biopsy shows glandular structures with mucin production. What is the most likely diagnosis, what cell type did it arise from, and what molecular testing should be ordered?

A CT report describes a peripheral lung lesion with 'ground-glass opacity' and no solid component. Pathology shows tumor cells spreading along intact alveolar walls without stromal invasion. What growth pattern is this, and what does it imply about the invasive status of the tumor?

A patient with lung adenocarcinoma is found to have an ALK rearrangement on molecular testing. A resident proposes starting erlotinib. Is this correct? What is the appropriate targeted agent, and which mutation would erlotinib actually target?

A patient with a peripheral lung mass develops painful swelling of both wrists and ankles with digital clubbing. X-ray shows periosteal new bone formation. What paraneoplastic syndrome is this, and with which type of lung cancer is it most classically associated?

NSCLC — Adenocarcinoma

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics